JPWO2022040204A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022040204A5
JPWO2022040204A5 JP2023511995A JP2023511995A JPWO2022040204A5 JP WO2022040204 A5 JPWO2022040204 A5 JP WO2022040204A5 JP 2023511995 A JP2023511995 A JP 2023511995A JP 2023511995 A JP2023511995 A JP 2023511995A JP WO2022040204 A5 JPWO2022040204 A5 JP WO2022040204A5
Authority
JP
Japan
Prior art keywords
polypeptide
acid sequence
coronavirus
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023511995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538085A5 (https=
JP2023538085A (ja
Publication date
Priority claimed from US16/996,740 external-priority patent/US11149286B1/en
Application filed filed Critical
Publication of JP2023538085A publication Critical patent/JP2023538085A/ja
Publication of JP2023538085A5 publication Critical patent/JP2023538085A5/ja
Publication of JPWO2022040204A5 publication Critical patent/JPWO2022040204A5/ja
Priority to JP2025135332A priority Critical patent/JP2025183225A/ja
Pending legal-status Critical Current

Links

JP2023511995A 2020-08-17 2021-08-17 アデノウイルスベクター及びアデノウイルスベクターの使用方法 Pending JP2023538085A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025135332A JP2025183225A (ja) 2020-08-17 2025-08-15 アデノウイルスベクター及びアデノウイルスベクターの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063066740P 2020-08-17 2020-08-17
US63/066,740 2020-08-17
US16/996,740 US11149286B1 (en) 2020-08-17 2020-08-18 Adenovirus vectors and methods for using adenovirus vectors
US16/996,740 2020-08-18
PCT/US2021/046333 WO2022040204A1 (en) 2020-08-17 2021-08-17 Adenovirus vectors and methods for using adenovirus vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025135332A Division JP2025183225A (ja) 2020-08-17 2025-08-15 アデノウイルスベクター及びアデノウイルスベクターの使用方法

Publications (3)

Publication Number Publication Date
JP2023538085A JP2023538085A (ja) 2023-09-06
JP2023538085A5 JP2023538085A5 (https=) 2024-08-13
JPWO2022040204A5 true JPWO2022040204A5 (https=) 2024-08-13

Family

ID=78083221

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023511995A Pending JP2023538085A (ja) 2020-08-17 2021-08-17 アデノウイルスベクター及びアデノウイルスベクターの使用方法
JP2025135332A Pending JP2025183225A (ja) 2020-08-17 2025-08-15 アデノウイルスベクター及びアデノウイルスベクターの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025135332A Pending JP2025183225A (ja) 2020-08-17 2025-08-15 アデノウイルスベクター及びアデノウイルスベクターの使用方法

Country Status (11)

Country Link
US (4) US11149286B1 (https=)
EP (1) EP4196092A4 (https=)
JP (2) JP2023538085A (https=)
KR (1) KR20230079359A (https=)
CN (1) CN116887820A (https=)
AU (1) AU2021329309A1 (https=)
BR (1) BR112023002932A2 (https=)
CA (1) CA3189832A1 (https=)
MX (1) MX2023002008A (https=)
WO (1) WO2022040204A1 (https=)
ZA (1) ZA202303601B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111738A2 (en) 2008-03-06 2009-09-11 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US11149286B1 (en) 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
US20240269262A1 (en) * 2021-04-09 2024-08-15 University Of Florida Research Foundation, Incorporated Methods, kits, and approaches for viral vaccines
JP2025531348A (ja) * 2022-09-19 2025-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ アデノウイルスベクターを使用して、哺乳動物を免疫化するための方法及び材料
WO2025129186A1 (en) * 2023-12-14 2025-06-19 The Trustees Of The University Of Pennsylvania Clostridioides difficile vaccine and methods of use
WO2025196724A1 (en) * 2024-03-21 2025-09-25 Moat Biotechnology Corporation Methods for inducing immune responses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
US20060062764A1 (en) 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
EP2173376B1 (en) * 2007-08-02 2015-03-25 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
WO2009111738A2 (en) 2008-03-06 2009-09-11 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
EP3466443B1 (en) * 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
CA3120715A1 (en) * 2018-11-21 2020-05-28 Mayo Foundation For Medical Education And Research Adenoviruses and methods for using adenoviruses
CN111358943A (zh) * 2020-03-03 2020-07-03 重庆医科大学附属永川医院 一种新冠病毒的双靶向免疫增强型多价疫苗及其制备方法
CN111218459B (zh) * 2020-03-18 2020-09-11 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
GB202004974D0 (en) * 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
CN111529685A (zh) * 2020-04-21 2020-08-14 厦门诺康得生物科技有限公司 抗呼吸道病毒感染的鼻腔喷雾制剂
RU2720614C9 (ru) * 2020-04-23 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CN111560076B (zh) * 2020-05-15 2021-05-07 广州百暨基因科技有限公司 一种嵌合抗原受体免疫细胞及其制备方法和应用
US11149286B1 (en) 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors

Similar Documents

Publication Publication Date Title
US6669942B2 (en) Defective adenoviruses including a therapeutic gene and an immunoprotectove gene
US6811774B2 (en) Defective recombinant adenoviruses expressing cytokines for antitumor treatment
Kiyono et al. NALT-versus Peyer's-patch-mediated mucosal immunity
RU2612788C2 (ru) Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение
Kusakabe et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine
US20090226485A1 (en) Recombinant Porcine Adenovirus Vector
JP2011036251A (ja) ウイルスベクターおよびその遺伝子治療のための使用
US11268108B2 (en) Replication competent adenoviral vectors
US8920813B2 (en) Adenoviral vector-based dengue fever vaccine
JPWO2022040204A5 (https=)
US5831062A (en) Use of the human interferon consensus gene for gene therapy
JP7607749B2 (ja) 新規コロナウイルス組換えスパイクタンパク質、それをコードするポリヌクレオチド、ポリヌクレオチドを含むベクター、およびベクターを含む、コロナウイルス感染を予防または処置するためのワクチン
KR20230113331A (ko) 인간 파필로마 바이러스 백신 및 hpv 연관된 질환에 대한 이의 용도
JPWO2020123773A5 (https=)
JP2005523942A (ja) 免疫療法のためのアデノウイルスベクター
CN102086453B (zh) 以粘蛋白1和生存素为靶点的肿瘤dna疫苗及病毒载体疫苗
RU2709659C1 (ru) Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты)
Braciak et al. Recombinant adenovirus vectors expressing interleukin‐5 and‐6 specifically enhance mucosal immunoglobulin A responses in the lung
JP2022536137A (ja) 粘膜ワクチン製剤
CN102732543A (zh) 以粘蛋白1和生存素为靶点的肿瘤基因工程疫苗
JP2003504316A (ja) 疾患を処置するためのアデノウイルスベクター
JP2011505837A (ja) アデノウイルス血清１４型に対するワクチン
CN1094974C (zh) 表达人白细胞介素12的重组腺病毒及其制法和用途
WO1992003574A1 (en) Cytokine production
US7264818B2 (en) BAV packaging regions and E1 transcriptional control regions